Back to Search Start Over

MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1.

Authors :
Kim N
Kim M
Yun S
Doh J
Greenberg PD
Kim TD
Choi I
Source :
The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2014 Jul; Vol. 134 (1), pp. 195-203. Date of Electronic Publication: 2014 Mar 31.
Publication Year :
2014

Abstract

Background: Perforin-1 (Prf1) is the predominant cytolytic protein secreted by natural killer (NK) cells. For a rapid immune response, resting NK cells contain high Prf1 mRNA concentrations while exhibiting minimal cytotoxicity caused by a blockage of Prf1 protein synthesis, implying that an unknown posttranscriptional regulatory mechanism exists.<br />Objective: We sought to determine whether microRNA-150 (miR-150) posttranscriptionally regulates Prf1 translation in both mouse and human NK cells at rest and at various time points after activation.<br />Methods: Mouse NK cells with a targeted deletion of miR-150 (miR-150(-/-) NK cells), primary human NK cells, and NK92 MI cells were used to investigate the role of miR-150 in NK cells. NK cell cytotoxicity assays and Western blotting proved that activated miR-150(-/-) NK cells expressed upregulated Prf1, augmenting NK cell cytotoxicity. When immunodeficient mice were injected with miR-150(-/-) NK cells, there was a significant reduction in tumor growth and metastasis of B16F10 melanoma.<br />Results: We report that miR-150 binds to 3' untranslated regions of mouse and human Prf1, posttranscriptionally downregulating its expression. Mouse wild-type NK cells displayed downregulated miR-150 expression in response to IL-15, which led to corresponding repression and induction of Prf1 during rest and after IL-15 activation, respectively.<br />Conclusion: Our results indicate that miR-150 is a common posttranscriptional regulator for Prf1 in mouse and human NK cells that represses NK cell lytic activity. Thus the therapeutic control of miR-150 in NK cells could enhance NK cell-based immunotherapy against cancer, providing a better clinical outcome.<br /> (Copyright © 2014 The Authors. Published by Mosby, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-6825
Volume :
134
Issue :
1
Database :
MEDLINE
Journal :
The Journal of allergy and clinical immunology
Publication Type :
Academic Journal
Accession number :
24698324
Full Text :
https://doi.org/10.1016/j.jaci.2014.02.018